CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma: An insight
The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical and non-clinical trends in the global CAR T-cell therapy for multiple myeloma.
Most of the pipeline therapeutics are in early stages of development; there is no CAR T-cell therapy approved to date for multiple myeloma treatment, but other treatments are available. A long-lasting and less-frequent dose can impact the overall multiple myeloma market.
In recent past, many pilot studies and early clinical trials have shown very promising results in the treatment of multiple myeloma with CAR T-cell therapy. However, the market has yet to witness the approval of the first CAR T-cell therapy for multiple myeloma, and it may take a few years from now. The currently available treatment for multiple myeloma include chemotherapy and other drugs, bisphosphonates, radiation, surgery, stem cell transplant, and plasmapheresis.
According to the National Cancer Institute (NIH), in 2017, there will be 30,280 new cases of myeloma and an estimated 12,590 deaths occur due to this disease in the US.
Covered in this report
The report covers the present scenario and the growth prospects of the car T-cell therapy for multiple myeloma. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
Technavio Announces the Publication of its Research Report - CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report
Technavio recognizes the following companies in the car T-cell therapy for multiple myeloma: Juno Therapeutics, Kite Pharma, Novartis, and Collectis.
The “Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma - A pipeline analysis report, 2017”, provides comprehensive insights about pipeline molecules across this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under CAR T-cell therapy for multiple myeloma.
This report provides information on the therapeutic development based on the CAR T-cell therapy for multiple myeloma dealing with all the pipeline drugs; comparative analysis at various stages covering Phase III, Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also highlights the dormant products.
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. They are engineered receptors, which graft an arbitrary specificity onto an immune effector cell (T-cell). CAR T-cell therapy uses an individual's own cells and “re-engineers” them to fight cancer. It is a very complex treatment.
Juno Therapeutics, Kite Pharma, Novartis, and Collectis.